{"entity":{"id":"nct06325748","kind":"trial","name":"SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS","aka":[],"tldr":"A phase 1 trial of SENTI-202 run by Senti Biosciences, active and no longer recruiting.","summary":"SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS is a phase 1 interventional study registered as NCT06325748 by Senti Biosciences, with 21 participants planned, started 2024-04-22. Conditions recorded: AML/MDS, CD33 Expressing Hematological Malignancies and FLT3 Expressing Hematological Malignancies. Interventions recorded: SENTI-202.","status":"active","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06325748","url":"https://clinicaltrials.gov/study/NCT06325748"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["senti-202"],"companies":["senti-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06325748","phase":"1","setting":"SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Malignancies","sponsor":"Senti Biosciences","enrolled":21,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06325748/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"senti-202","kind":"drug","name":"SENTI-202","route":"/drugs/senti-202/"}],"company":[{"id":"senti-biosciences","kind":"company","name":"Senti Biosciences","route":"/companies/senti-biosciences/"}]}}